Laboratory findings | Clinical findings | Radiographic findings | Interpretation of findings |
Glucocorticoid therapy (hydrocortisone) | |||
|
|
|
|
|
|
|
|
Mineralocorticoid therapy (fludrocortisone) | |||
|
|
|
|
|
|
|
|
17-OHP: 17-hydroxyprogesterone; PRA: plasma renin activity.
* 17-OHP should be measured in the early morning prior to administration of glucocorticoid medication.
¶ Expected growth velocity is determined by genetic height potential (midparental height), age, and pubertal stage. Refer to relevant UpToDate content on measurement of growth in children for additional information.
Δ Additional signs and symptoms of glucocorticoid excess (Cushing syndrome) include round face (usually notable when comparing photos), violaceous striae, muscle weakness, and mood lability.
◊ Signs of androgen excess include early pubic and axillary hair, hirsutism and/or amenorrhea in adolescent females, genital enlargement in males, clitoromegaly in females, and increased muscular habitus.
§ Defined as onset of puberty before age 8 years in assigned females and age 9 years in assigned males.
¥ Signs of dehydration and hypovolemia include dry mucous membranes, hypotension, and tachycardia.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟